Dr. Schuetze will provide an overview of the rationale for treatment of EHE with trametinib, an oral inhibitor of the MEK kinase; the trial design of 10015/SARC033; and the results of the primary and secondary study endpoints. The presentation will also include an update on exploratory investigation of blood-based biomarkers including hemoglobin, C-reactive protein, and connective tissue growth factor as prognostic and predictive factors in the patients with EHE who participated in the clinical trial.
TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
